Trevi outlines 200+ global trial sites as it targets FDA alignment for non-IPF-ILD chronic cough in H2 2026

Trevi Therapeutics (TRVI) Q2 2026 earnings call highlights: OCEAN-1/LAKE trial starts, OCEAN-2 timing, FDA alignment, and cash runway into 2030—read now.